Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 7Lymphoid 3Head & Neck 2Breast 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Wounds and Injuries 1Head and Neck Neoplasms 1Cancer Pain 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Gels × Breast × Clear all
NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Mayo Clinic

Phase 2 Terminated
65 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT05800834 2023-09-28

MorphineGEL

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
106 enrolled
BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡